Mr Christopher Brown

Research Fellow
NHMRC Clinical Trials Centre, Sydney Medical School

Telephone 02 9562 5039

Map

Biographical details

Chris Brown has been a Biostatistician with the NHMRC Clinical Trials Centre since August 2005. He returned to his former university (Bachelor of Science, mathematics and statistics) after working at statistical software company SPSS. He completed a Masters of Biostatistics and became a Research Fellow in 2009. He has experience in trial design, analysis, statistical computing and specialises in oncology. He was the COGNO group statistician and worked closely with the ALTG and AGITG. He is currently on extended leave at the National Cancer Registry Ireland.

Research interests

Chris' main research interests include randomisation, phase-II trial designs, methods of time-to-event analysis and genome wide association studies.

Selected grants

2013

  • Development and operational support for the Australasian Lung cancer Trials Group (ALTG) through the NHMRC Clinical Trial Centre: A NSW-led initiative; Pavlakis N, Boyer M, Stockler M, Dhillon H, Links M, Brown C, Lewis C, Stubbin I; Cancer Institute New South Wales/Cooperative Clinical Trial (CCT) Grants.
  • Nerve excitability assessment: a novel biomarker for the early detection of diabetic neuropathy; Krishnan A, Lin C, Brown C; National Health and Medical Research Council (NHMRC)/Project Grants.
  • The biological basis of success or failure to the anti-VEGF agent, bevacizumab in patients with recurrent glioblastoma; Simes R, McDonald K, Brown C, Yip S; Cancer Council New South Wales/Research Project Grants.

2012

  • Personalising care in resectable pancreas cancer. GAP-T: a study of imaging and molecular biomarkers to guide treatment of patients receiving preoperative chemotherapy followed by surgery.; Barbour A, Goldstein D, Goldstein D, Kench J, Yip S, Brown C, Hicks R, Chang D; National Health and Medical Research Council (NHMRC)/Project Grants.

2011

  • DOCetaxel with or without radiation Therapy for resectable Oesophageal adenocarcinoma based on early PET Response to induction chemotherapy (DOCTOR); Goldstein D, Brown C, Yip S, Barbour A; National Health and Medical Research Council (NHMRC)/Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Dahlen, H., Tracy, S., Tracy, M., Bisits, A., Brown, C., Thornton, C. (2014). Rates of obstetric intervention and associated perinatal mortality and morbidity among low-risk women giving birth in private and public hospitals (2000-2008): a linked data population-based cohort study. BMJ Open, 4(5), 1-10. [More Information]
  • Nowak, A., Brown, C., Millward, M., Creaney, J., Byrne, M., Hughes, B., Kremmidiotis, G., Bibby, D., Leske, A., Mitchell, P., Pavlakis, N., Stockler, M., et al (2013). A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer, 81(3), 422-427. [More Information]
  • Lee, C., Simes, R., Brown, C., Gebski, V., Pfisterer, J., Swart, A., Berton-Rigaud, D., Plante, M., Skeie-Jensen, T., Vergote, I., Lord, S., et al (2013). A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Annals of Oncology, 24(4), 937-943. [More Information]
  • Lee, C., Brown, C., Gralla, R., Hirsh, V., Thongprasert, S., Tsai, C., Tan, E., Ho, J., Chu, D., Zaatar, A., Gebski, V., et al (2013). Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. National Cancer Institute. Journal, 105(9), 595-605. [More Information]
  • Houghton, B., Chalasani, V., Hayne, D., Grimison, P., Brown, C., Patel, M., Davis, I., Stockler, M. (2013). Intravesical chemotherapy plus bacille Calmette-Guerin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. BJU International, 111(6), 977-933. [More Information]
  • Fox, P., Hudson, M., Brown, C., Lord, S., Gebski, V., de Souza, P., Lee, C. (2013). Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. British Journal of Cancer, 109(1), 147-153. [More Information]
  • Priddis, H., Dahlen, H., Schmied, V., Sneddon, A., Kettle, C., Brown, C., Thornton, C. (2013). Risk of recurrence, subsequent mode of birth and morbidity for women who experienced severe perineal trauma in a first birth in New South Wales between 2000 -2008: a population based data linkage study. BMC Pregnancy and Childbirth, 13, 1-7. [More Information]
  • Dahlen, H., Priddis, H., Schmied, V., Sneddon, A., Kettle, C., Brown, C., Thornton, C. (2013). Trends and risk factors for severe perineal trauma during childbirth in New South Wales between 2000 and 2008: a population-based data study. BMJ Open, 3(5), 1-7. [More Information]
  • Alexandre, J., Brown, C., Coeffic, D., Raban, N., Pfisterer, J., Maenpaa, J., Chalchal, H., Fitzharris, B., Volgger, B., Vergote, I., et al (2012). CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. British Journal of Cancer, 106(4), 633-637. [More Information]
  • Wagner, U., Marth, C., Largillier, R., Kaern, J., Brown, C., Heywood, M., Bonaventura, T., Vergote, I., Piccirillo, M., Fossati, R., et al (2012). Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. British Journal of Cancer, 107(4), 588-591. [More Information]
  • Brundage, M., Gropp, M., Mefti, F., Mann, K., Lund, B., Gebski, V., Wolfram, G., Reed, N., Pignata, S., Ferrero, A., Brown, C., et al (2012). Health-related quality of life in recurrent platinum-sensitive ovarian cancer - results from the CALYPSO trial. Annals of Oncology, 23(8), 2020-2027. [More Information]
  • Ong, K., Rye, K., O'Connell, R., Jenkins, A., Brown, C., Xu, A., Sullivan, D., Barter, P., Keech, A. (2012). Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 97(12), 4701-4708. [More Information]
  • Dahlen, H., Tracy, S., Tracy, M., Bisits, A., Brown, C., Thornton, C. (2012). Rates of obstetric intervention among low-risk women giving birth in private and public hospitals in NSW: a population-based descriptive study. BMJ Open, 2(5), 1-8. [More Information]
  • Goldstein, D., Spry, N., Cummins, M., Brown, C., van Hazel, G., Carroll, S., Selva-Nayagam, S., Borg, M., Ackland, S., Wratten, C., Hruby, G., Horvath, L., Gebski, V., et al (2012). The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. British Journal of Cancer, 106(1), 61-69. [More Information]
  • Lee, C., Gurney, H., Brown, C., Sorio, R., Donadello, N., Tulunay, G., Meier, W., Bacon, M., Maenpaa, J., Petru, E., Gebski, V., Lord, S., Simes, R., et al (2011). Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. British Journal of Cancer, 105(3), 360-365. [More Information]
  • Lee, C., Friedlander, M., Brown, C., Gebski, V., Georgoulopoulos, A., Vergote, I., Pignata, S., Donadello, N., Schmalfeldt, B., Delva, R., Lord, S., Simes, R., et al (2011). Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. National Cancer Institute. Journal, 103(17), 1338-1342. [More Information]
  • Blinman, P., McLachlan, S., Nowak, A., Duric, V., Brown, C., Wright, G., Millward, M., Fong, K., Stockler, M. (2011). Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: What makes it worthwhile? Lung Cancer, 72(2), 213-218. [More Information]
  • McIntyre, S., Badawi, N., Brown, C., Blair, E. (2011). Population Case-Control Study of Cerebral Palsy: Neonatal Predictors for Low-Risk Term Singletons. Pediatrics (English Edition), 127(3), e667-e673. [More Information]
  • Lee, C., Simes, R., Brown, C., Lord, S., Wagner, U., Plante, M., Vergote, I., Pisano, C., Parma, G., Burges, A., Gebski, V., et al (2011). Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. British Journal of Cancer, 105(8), 1144-1150. [More Information]
  • Clarke, S., Yip, S., Brown, C., van Hazel, G., Ransom, D., Goldstein, D., Jeffrey, G., Tebbutt, N., Buck, M., Lowenthal, R., Boland, A., Gebski, V., Simes, R., et al (2011). Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European Journal of Cancer, 47(12), 1826-1836. [More Information]
  • Goldstein, D., Gainford, M., Brown, C., Tebbutt, N., Ackland, S., van Hazel, G., Jefford, M., Abdi, E., Selva-Nayagam, S., Gebski, V., Miller, D., et al (2010). Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemotherapy and Pharmacology, , 1-7. [More Information]
  • Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P., Volgger, B., Vergote, I., Pignata, S., Ferrero, A., Brown, C., et al (2010). Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. Journal of Clinical Oncology, 28(20), 3323-3329. [More Information]
  • Sy, R., Bannon, P., Bayfield, M., Brown, C., Kritharides, L. (2009). Survivor Treatment Selection Bias and Outcomes Research: A Case Study of Surgery in Infective Endocarditis. Circulation. Cardiovascular Quality and Outcomes, 2(5), 469-474. [More Information]

2014

  • Dahlen, H., Tracy, S., Tracy, M., Bisits, A., Brown, C., Thornton, C. (2014). Rates of obstetric intervention and associated perinatal mortality and morbidity among low-risk women giving birth in private and public hospitals (2000-2008): a linked data population-based cohort study. BMJ Open, 4(5), 1-10. [More Information]

2013

  • Nowak, A., Brown, C., Millward, M., Creaney, J., Byrne, M., Hughes, B., Kremmidiotis, G., Bibby, D., Leske, A., Mitchell, P., Pavlakis, N., Stockler, M., et al (2013). A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer, 81(3), 422-427. [More Information]
  • Lee, C., Simes, R., Brown, C., Gebski, V., Pfisterer, J., Swart, A., Berton-Rigaud, D., Plante, M., Skeie-Jensen, T., Vergote, I., Lord, S., et al (2013). A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Annals of Oncology, 24(4), 937-943. [More Information]
  • Lee, C., Brown, C., Gralla, R., Hirsh, V., Thongprasert, S., Tsai, C., Tan, E., Ho, J., Chu, D., Zaatar, A., Gebski, V., et al (2013). Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. National Cancer Institute. Journal, 105(9), 595-605. [More Information]
  • Houghton, B., Chalasani, V., Hayne, D., Grimison, P., Brown, C., Patel, M., Davis, I., Stockler, M. (2013). Intravesical chemotherapy plus bacille Calmette-Guerin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. BJU International, 111(6), 977-933. [More Information]
  • Fox, P., Hudson, M., Brown, C., Lord, S., Gebski, V., de Souza, P., Lee, C. (2013). Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. British Journal of Cancer, 109(1), 147-153. [More Information]
  • Priddis, H., Dahlen, H., Schmied, V., Sneddon, A., Kettle, C., Brown, C., Thornton, C. (2013). Risk of recurrence, subsequent mode of birth and morbidity for women who experienced severe perineal trauma in a first birth in New South Wales between 2000 -2008: a population based data linkage study. BMC Pregnancy and Childbirth, 13, 1-7. [More Information]
  • Dahlen, H., Priddis, H., Schmied, V., Sneddon, A., Kettle, C., Brown, C., Thornton, C. (2013). Trends and risk factors for severe perineal trauma during childbirth in New South Wales between 2000 and 2008: a population-based data study. BMJ Open, 3(5), 1-7. [More Information]

2012

  • Alexandre, J., Brown, C., Coeffic, D., Raban, N., Pfisterer, J., Maenpaa, J., Chalchal, H., Fitzharris, B., Volgger, B., Vergote, I., et al (2012). CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. British Journal of Cancer, 106(4), 633-637. [More Information]
  • Wagner, U., Marth, C., Largillier, R., Kaern, J., Brown, C., Heywood, M., Bonaventura, T., Vergote, I., Piccirillo, M., Fossati, R., et al (2012). Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. British Journal of Cancer, 107(4), 588-591. [More Information]
  • Brundage, M., Gropp, M., Mefti, F., Mann, K., Lund, B., Gebski, V., Wolfram, G., Reed, N., Pignata, S., Ferrero, A., Brown, C., et al (2012). Health-related quality of life in recurrent platinum-sensitive ovarian cancer - results from the CALYPSO trial. Annals of Oncology, 23(8), 2020-2027. [More Information]
  • Ong, K., Rye, K., O'Connell, R., Jenkins, A., Brown, C., Xu, A., Sullivan, D., Barter, P., Keech, A. (2012). Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 97(12), 4701-4708. [More Information]
  • Dahlen, H., Tracy, S., Tracy, M., Bisits, A., Brown, C., Thornton, C. (2012). Rates of obstetric intervention among low-risk women giving birth in private and public hospitals in NSW: a population-based descriptive study. BMJ Open, 2(5), 1-8. [More Information]
  • Goldstein, D., Spry, N., Cummins, M., Brown, C., van Hazel, G., Carroll, S., Selva-Nayagam, S., Borg, M., Ackland, S., Wratten, C., Hruby, G., Horvath, L., Gebski, V., et al (2012). The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. British Journal of Cancer, 106(1), 61-69. [More Information]

2011

  • Lee, C., Gurney, H., Brown, C., Sorio, R., Donadello, N., Tulunay, G., Meier, W., Bacon, M., Maenpaa, J., Petru, E., Gebski, V., Lord, S., Simes, R., et al (2011). Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. British Journal of Cancer, 105(3), 360-365. [More Information]
  • Lee, C., Friedlander, M., Brown, C., Gebski, V., Georgoulopoulos, A., Vergote, I., Pignata, S., Donadello, N., Schmalfeldt, B., Delva, R., Lord, S., Simes, R., et al (2011). Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. National Cancer Institute. Journal, 103(17), 1338-1342. [More Information]
  • Blinman, P., McLachlan, S., Nowak, A., Duric, V., Brown, C., Wright, G., Millward, M., Fong, K., Stockler, M. (2011). Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: What makes it worthwhile? Lung Cancer, 72(2), 213-218. [More Information]
  • McIntyre, S., Badawi, N., Brown, C., Blair, E. (2011). Population Case-Control Study of Cerebral Palsy: Neonatal Predictors for Low-Risk Term Singletons. Pediatrics (English Edition), 127(3), e667-e673. [More Information]
  • Lee, C., Simes, R., Brown, C., Lord, S., Wagner, U., Plante, M., Vergote, I., Pisano, C., Parma, G., Burges, A., Gebski, V., et al (2011). Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. British Journal of Cancer, 105(8), 1144-1150. [More Information]
  • Clarke, S., Yip, S., Brown, C., van Hazel, G., Ransom, D., Goldstein, D., Jeffrey, G., Tebbutt, N., Buck, M., Lowenthal, R., Boland, A., Gebski, V., Simes, R., et al (2011). Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European Journal of Cancer, 47(12), 1826-1836. [More Information]

2010

  • Goldstein, D., Gainford, M., Brown, C., Tebbutt, N., Ackland, S., van Hazel, G., Jefford, M., Abdi, E., Selva-Nayagam, S., Gebski, V., Miller, D., et al (2010). Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemotherapy and Pharmacology, , 1-7. [More Information]
  • Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P., Volgger, B., Vergote, I., Pignata, S., Ferrero, A., Brown, C., et al (2010). Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. Journal of Clinical Oncology, 28(20), 3323-3329. [More Information]

2009

  • Sy, R., Bannon, P., Bayfield, M., Brown, C., Kritharides, L. (2009). Survivor Treatment Selection Bias and Outcomes Research: A Case Study of Surgery in Infective Endocarditis. Circulation. Cardiovascular Quality and Outcomes, 2(5), 469-474. [More Information]

To update your profile click here. For support on your academic profile contact .